Abstract
CX3CL1 (Fractalkine) is a multifunctional inflammatory chemokine with a single receptor CX3CR1. The biological effects elicited by CX3CL1 on surrounding cells vary depending on a number of factors including its structure, the expression pattern of CX3CR1, and the cell type. For instance, the transmembrane form of CX3CL1 primarily serves as an adhesion molecule, but when cleaved to a soluble form, CX3CL1 predominantly functions as a chemotactic cytokine (Fig. 1.1). However, the biological functions of CX3CL1 also extend to immune cell survival and retention. The pro-inflammatory nature of CX3CR1-expressing immune cells place the CX3CL1:CX3CR1 axis as a central player in multiple inflammatory disorders and position this chemokine pathway as a potential therapeutic target. However, the emerging role of this chemokine pathway in the maintenance of effector memory cytotoxic T cell populations implicates it as a key chemokine in anti-viral and anti-tumor immunity, and therefore an unsuitable therapeutic target in inflammation. The reported role of CX3CL1 as a key regulator of cytotoxic T cell-mediated immunity is supported by several studies that demonstrate CX3CL1 as an important TIL-recruiting chemokine and a positive prognostic factor in colorectal, breast, and lung cancer. Such reports are conflicting with an overwhelming number of studies demonstrating a pro-tumorigenic and pro-metastatic role of CX3CL1 across multiple blood and solid malignancies.
This chapter will review the unique structure, function, and biology of CX3CL1 and address the diversity of its biological effects in the immune system and the tumor microenvironment. Overall, this chapter highlights how we have just scratched the surface of CX3CL1’s capabilities and suggests that further in-depth and mechanistic studies incorporating all CX3CL1 interactions must be performed to fully appreciate its role in cancer and its potential as a therapeutic target.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bazan JF et al (1997) A new class of membrane-bound chemokine with a CX3C motif. Nature 385(6617):640–644
Fong AM et al (1998) Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 188(8):1413–1419
Imai T et al (1997) Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91(4):521–530
Garton KJ et al (2001) Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 276(41):37993–38001
Tsou CL, Haskell CA, Charo IF (2001) Tumor necrosis factor-alpha-converting enzyme mediates the inducible cleavage of fractalkine. J Biol Chem 276(48):44622–44626
Conroy MJ et al (1867) Identifying a Novel Role for Fractalkine (CX3CL1) in Memory CD8+ T Cell Accumulation in the Omentum of Obesity-Associated Cancer Patients. Front Immunol 9:2018
Bottcher JP et al (2015) Functional classification of memory CD8(+) T cells by CX3CR1 expression. Nat Commun 6:8306
White GE et al (2014) Fractalkine promotes human monocyte survival via a reduction in oxidative stress. Arterioscler Thromb Vasc Biol 34(12):2554–2562
Mionnet C et al (2010) CX3CR1 is required for airway inflammation by promoting T helper cell survival and maintenance in inflamed lung. Nat Med 16(11):1305–1312
Shin MS et al (2015) DNA Methylation Regulates the Differential Expression of CX3CR1 on Human IL-7Ralphalow and IL-7Ralphahigh Effector Memory CD8+ T Cells with Distinct Migratory Capacities to the Fractalkine. J Immunol 195(6):2861–2869
Landsman L et al (2009) CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood 113(4):963–972
Nakayama T et al (2010) Eotaxin-3/CC chemokine ligand 26 is a functional ligand for CX3CR1. J Immunol 185(11):6472–6479
Nishimura M et al (2002) Dual functions of fractalkine/CX3C ligand 1 in trafficking of perforin+/granzyme B+ cytotoxic effector lymphocytes that are defined by CX3CR1 expression. J Immunol 168(12):6173–6180
Wada A et al (2015) Role of chemokine CX3CL1 in progression of multiple myeloma via CX3CR1 in bone microenvironments. Oncol Rep 33(6):2935–2939
Corcione A, Ferretti E, Pistoia V (2012) CX3CL1/fractalkine is a novel regulator of normal and malignant human B cell function. J Leukoc Biol 92(1):51–58
Liu P et al (2018) CX3CL1/fractalkine enhances prostate cancer spinal metastasis by activating the Src/FAK pathway. Int J Oncol 53(4):1544–1556
Huang LY et al (2012) Fractalkine upregulates inflammation through CX3CR1 and the Jak-Stat pathway in severe acute pancreatitis rat model. Inflammation 35(3):1023–1030
Lee YS et al (2018) CX3CR1 differentiates F4/80(low) monocytes into pro-inflammatory F4/80(high) macrophages in the liver. Sci Rep 8(1):15076
Kitaura M et al (1999) Molecular cloning of a novel human CC chemokine (Eotaxin-3) that is a functional ligand of CC chemokine receptor 3. J Biol Chem 274(39):27975–27980
Petkovic V et al (2004) Eotaxin-3/CCL26 is a natural antagonist for CC chemokine receptors 1 and 5. A human chemokine with a regulatory role. J Biol Chem 279(22):23357–23363
Ogilvie P et al (2003) Eotaxin-3 is a natural antagonist for CCR2 and exerts a repulsive effect on human monocytes. Blood 102(3):789–794
El-Shazly AE et al (2013) Novel cooperation between CX3CL1 and CCL26 inducing NK cell chemotaxis via CX3CR1: a possible mechanism for NK cell infiltration of the allergic nasal tissue. Clin Exp Allergy 43(3):322–331
Batool A et al (2018) A miR-125b/CSF1-CX3CL1/tumor-associated macrophage recruitment axis controls testicular germ cell tumor growth. Cell Death Dis 9(10):962
Geismann C et al (2018) TRAIL/NF-kappaB/CX3CL1 mediated onco-immuno crosstalk leading to TRAIL resistance of pancreatic cancer cell lines. Int J Mol Sci 19:6
Lavergne E et al (2003) Fractalkine mediates natural killer-dependent antitumor responses in vivo. Cancer Res 63(21):7468–7474
Liang Y et al (2018) CX3CL1 involves in breast cancer metastasizing to the spine via the Src/FAK signaling pathway. J Cancer 9(19):3603–3612
Liu W et al (2017) CX3CL1: a potential chemokine widely involved in the process spinal metastases. Oncotarget 8(9):15213–15219
Marchesi F et al (2008) The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma. Cancer Res 68(21):9060–9069
Stout MC et al (2018) Inhibition of CX3CR1 reduces cell motility and viability in pancreatic adenocarcinoma epithelial cells. Biochem Biophys Res Commun 495(3):2264–2269
Tang J et al (2016) CX3CL1 increases invasiveness and metastasis by promoting epithelial-to-mesenchymal transition through the TACE/TGF-alpha/EGFR pathway in hypoxic androgen-independent prostate cancer cells. Oncol Rep 35(2):1153–1162
Tardaguila M et al (2013) CX3CL1 promotes breast cancer via transactivation of the EGF pathway. Cancer Res 73(14):4461–4473
Xin H et al (2005) Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells. Eur J Immunol 35(5):1371–1380
Nukiwa M et al (2006) Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors. Eur J Immunol 36(4):1019–1027
Zeng Y et al (2005) Fractalkine gene therapy for neuroblastoma is more effective in combination with targeted IL-2. Cancer Lett 228(1–2):187–193
Siddiqui I et al (2016) Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient. J Immunother Cancer 4:21
Yan Y et al (2018) CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. JCI Insight 3:8
Hyakudomi M et al (2008) Increased expression of fractalkine is correlated with a better prognosis and an increased number of both CD8+ T cells and natural killer cells in gastric adenocarcinoma. Ann Surg Oncol 15(6):1775–1782
Ohta M et al (2005) The high expression of Fractalkine results in a better prognosis for colorectal cancer patients. Int J Oncol 26(1):41–47
Park MH, Lee JS, Yoon JH (2012) High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumor-infiltrating CD8+ T cells, natural killer cells, and dendritic cells in breast carcinoma. J Surg Oncol 106(4):386–392
Tsang JY et al (2013) CX3CL1 expression is associated with poor outcome in breast cancer patients. Breast Cancer Res Treat 140(3):495–504
Schmall A et al (2015) Macrophage and cancer cell cross-talk via CCR2 and CX3CR1 is a fundamental mechanism driving lung cancer. Am J Respir Crit Care Med 191(4):437–447
Liu J et al (2019) Increased CX3CL1 mRNA expression level is a positive prognostic factor in patients with lung adenocarcinoma. Oncol Lett 17(6):4877–4890
Okuma A et al (2017) p16(Ink4a) and p21(Cip1/Waf1) promote tumour growth by enhancing myeloid-derived suppressor cells chemotaxis. Nat Commun 8(1):2050
Obermajer N et al (2011) PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res 71(24):7463–7470
Kalinski P (2012) Regulation of immune responses by prostaglandin E2. J Immunol 188(1):21–28
Xu X et al (2012) High expression of CX3CL1/CX3CR1 axis predicts a poor prognosis of pancreatic ductal adenocarcinoma. J Gastrointest Surg 16(8):1493–1498
Liu JF, Tsao YT, Hou CH (2017) Fractalkine/CX3CL1 induced intercellular adhesion molecule-1-dependent tumor metastasis through the CX3CR1/PI3K/Akt/NF-kappaB pathway in human osteosarcoma. Oncotarget 8(33):54136–54148
Ren H et al (2013) The CX3CL1/CX3CR1 reprograms glucose metabolism through HIF-1 pathway in pancreatic adenocarcinoma. J Cell Biochem 114(11):2603–2611
Su YC et al (2018) Differential impact of CX3CL1 on lung cancer prognosis in smokers and non-smokers. Mol Carcinog 57(5):629–639
Staniland AA et al (2010) Reduced inflammatory and neuropathic pain and decreased spinal microglial response in fractalkine receptor (CX3CR1) knockout mice. J Neurochem 114(4):1143–1157
Shah R et al (2011) Fractalkine is a novel human adipochemokine associated with type 2 diabetes. Diabetes 60(5):1512–1518
Souza GR et al (2013) Fractalkine mediates inflammatory pain through activation of satellite glial cells. Proc Natl Acad Sci U S A 110(27):11193–11198
Xueyao Y et al (2014) Circulating fractalkine levels predict the development of the metabolic syndrome. Int J Endocrinol 2014:715148
Cefalu WT (2011) Fractalkine: a cellular link between adipose tissue inflammation and vascular pathologies. Diabetes 60(5):1380–1382
Desalegn G, Pabst O (2019) Inflammation triggers immediate rather than progressive changes in monocyte differentiation in the small intestine. Nat Commun 10(1):3229
Dorgham K et al (2009) An engineered CX3CR1 antagonist endowed with anti-inflammatory activity. J Leukoc Biol 86(4):903–911
Erreni M et al (2016) The fractalkine-receptor axis improves human colorectal cancer prognosis by limiting tumor metastatic dissemination. J Immunol 196(2):902–914
Renehan AG et al (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371(9612):569–578
Conroy MJ et al (2016) Parallel profiles of inflammatory and effector memory T cells in visceral fat and liver of obesity-associated cancer patients. Inflammation 39(5):1729–1736
Lysaght J et al (2011) T lymphocyte activation in visceral adipose tissue of patients with oesophageal adenocarcinoma. Br J Surg 98(7):964–974
Conroy MJ et al (2016) CCR1 antagonism attenuates T cell trafficking to omentum and liver in obesity-associated cancer. Immunol Cell Biol 94(6):531–537
Kavanagh ME et al (2019) Altered T cell migratory capacity in the progression from barrett oesophagus to oesophageal adenocarcinoma. Cancer Microenviron 12(1):57–66
Shen F et al (2016) Novel small-molecule CX3CR1 antagonist impairs metastatic seeding and colonization of breast cancer cells. Mol Cancer Res 14(6):518–527
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Conroy, M.J., Lysaght, J. (2020). CX3CL1 Signaling in the Tumor Microenvironment. In: Birbrair, A. (eds) Tumor Microenvironment. Advances in Experimental Medicine and Biology, vol 1231. Springer, Cham. https://doi.org/10.1007/978-3-030-36667-4_1
Download citation
DOI: https://doi.org/10.1007/978-3-030-36667-4_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-36666-7
Online ISBN: 978-3-030-36667-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)